Medicine

Perioperative immunotherapy for sac cancer cells

.ANALYSIS HIGHLIGHT.16 October 2024.

In the NIAGARA litigation, the addition of perioperative durvalumab to standard procedure for muscle-invasive bladder cancer cells strengthened event-free as well as in general survival, denoting a brand new procedure possibility for this problem.